Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 3 de 3
1.
World J Clin Cases ; 10(22): 7968-7972, 2022 Aug 06.
Article En | MEDLINE | ID: mdl-36158482

BACKGROUND: Patients diagnosed with non-small-cell lung cancer with activated epidermal growth factor receptor mutations are more likely to develop leptomeningeal (LM) metastasis than other types of lung cancers and have a poor prognosis. Early diagnosis and effective treatment of leptomeningeal carcinoma can improve the prognosis. CASE SUMMARY: A 55-year-old female with a progressive headache and vomiting for one month was admitted to Peking University First Hospital. She was diagnosed with lung adenocarcinoma with osseous metastasis 10 months prior to admittance. epidermal growth factor receptor (EGFR) mutation was detected by genomic examination, so she was first treated with gefitinib for 10 months before acquiring resistance. Cell-free cerebrospinal fluid (CSF) circulating tumor DNA detection by next-generation sequencing was conducted and indicated the EGFR-Thr790Met mutation, while biopsy and cytology from the patient's CSF and the first enhanced cranial magnetic resonance imaging (MRI) showed no positive findings. A month later, the enhanced MRI showed linear leptomeningeal enhancement, and the cytology and biochemical examination in CSF remained negative. Therefore, osimertinib (80 mg/d) was initiated as a second-line treatment, resulting in a good response within a month. CONCLUSION: This report suggests clinical benefit of osimertinib in LM patients with positive detection of the EGFR-Thr790Met mutation in CSF and proposes that the positive findings of CSF circulating tumor DNA as a liquid biopsy technology based on the detection of cancer-associated gene mutations may appear earlier than the imaging and CSF findings and may thus be helpful for therapy. Moreover, the routine screening of chest CT with the novel coronavirus may provide unexpected benefits.

2.
Cell Mol Neurobiol ; 41(8): 1707-1714, 2021 Nov.
Article En | MEDLINE | ID: mdl-32804313

The present study explored the modulating apoptosis effect of hydrogen sulfide (H2S) in subarachnoid hemorrhage (SAH) rats and its exact mechanism. A rat SAH model established by intravascular puncturing was used for the present study. After giving NaHS (donor of H2S), an L-type calcium channel opener (Bay K8644), or a calcium channel agonist (nifedipine), the neurological function of the rats, associated pathological changes, and expression of apoptosis-related proteins (Bcl-2, Bax, and caspase-3) and microtubule-associated protein (MAP-2) were examined. The concentration of H2S and expression of cystathionine beta synthase in the hippocampus changed upon early brain injury (EBI) after SAH. Compared with the SAH group, the neurological function of the rats and microstructure observed by electron microscopy were better in the SAH + NaHS group and SAH + Bay K8644 group. It was observed that apoptosis was more obvious in the SAH group than in the control group and was alleviated in the SAH + NaHS group. Furthermore, the alleviating effect of NaHS was partially weakened by nifedipine, indicating that the effect of anti-apoptosis in H2S might be correlated with the calcium channel. The expression of Bax and caspase-3 was elevated, while the expression of Bcl-2 decreased in the SAH group but improved in the SAH + NaHS and SAH + Bay K8644 group. Compared with the SAH + NaHS group, the expression of pro-apoptotic proteins was higher in the SAH + NaHS + nifedipine group. Therefore, upon EBI following SAH, the H2S system plays an important neurological protective effect by modulating the function of the L-type calcium channel and inhibiting apoptosis.


Brain Injuries/metabolism , Brain/metabolism , Calcium Channels, L-Type/metabolism , Hydrogen Sulfide/metabolism , Neuroprotection/physiology , Subarachnoid Hemorrhage/metabolism , 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester/pharmacology , Animals , Brain/drug effects , Brain Injuries/prevention & control , Calcium Channel Agonists/pharmacology , Male , Neuroprotection/drug effects , Rats , Rats, Sprague-Dawley , Subarachnoid Hemorrhage/prevention & control , Sulfites/pharmacology
3.
Article Zh | WPRIM | ID: wpr-674404

Objective To investigate.the survival rates in a follow-up group of patient with primary liver cancer.Methods The follow-up data of new primary liver cancer cases between year 2001-2004 in Xuhui district was investigated.The age distribution of patients was described.Survival rate was analyzed with single and multiple Cox proportional hazards regression model,respectively.Results The age proportion distribution of patients showed double apexes with one in age 45~50 and another in age 70~75.The arithmetic mean of survival month was 16.4 with 95%CI 14.8~18.1 and median month was 6.9.It was no significance between male and female.Patients who had liver operation owned longer survival time,RR=0.315 5(95%CI 0.243 2~ 0.4093).The sutdy showed 5-year survival rate was 40.90%and 3.95%for patients with or without operation,respectively.It had no significant effect on survival time by gender,age and family history.Conclusion The screening test and intervention in high-risk people shall be done preferentially before peak age,so as to find primary liver cancer earlier,and the more patients can accept a suitable surgery care,the more they can obtain longer survival time.

...